A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986322 in Healthy Adult Male Participants
Latest Information Update: 02 Apr 2024
Price :
$35 *
At a glance
- Drugs BMS 986322 (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Mar 2024 Status changed from not yet recruiting to completed.
- 20 Oct 2023 New trial record